S'abonner

Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age - 28/08/11

Doi : 10.1016/j.jaci.2011.04.060 
Hans Bisgaard, MD, DMSc a, , Nan Li, MD, PhD a, b, c, Klaus Bonnelykke, MD, PhD a, Bo Lund Krogsgaard Chawes, MD, PhD a, Thomas Skov, MSc, PhD d, Georg Paludan-Müller, MSc, PhD a, Jakob Stokholm, MD a, Birgitte Smith, MD b, Karen Angeliki Krogfelt, MSc, PhD b
a Copenhagen Prospective Studies on Asthma in Childhood, Health Sciences, University of Copenhagen, Copenhagen University Hospital, Gentofte, Copenhagen, Denmark 
b Department of Microbiological Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark 
c Department of Pulmonary Medicine, Peking University First Hospital, Beijing, China 
d Department of Food Science, Quality and Technology, Faculty of Life Sciences, University of Copenhagen, Copenhagen, Denmark 

Reprint requests: Hans Bisgaard, MD, DMSc, Copenhagen Prospective Studies on Asthma in Childhood, Health Sciences, University of Copenhagen, and the Danish Pediatric Asthma Center, Copenhagen University Hospital, Gentofte, Copenhagen DK-2820, Denmark.

Abstract

Background

Changes in the human microbiome have been suggested as a risk factor for a number of lifestyle-related disorders, such as atopic diseases, possibly through a modifying influence on immune maturation in infancy.

Objectives

We aimed to explore the association between neonatal fecal flora and the development of atopic disorders until age 6 years, hypothesizing that the diversity of the intestinal microbiota influences disease development.

Methods

We studied the intestinal microbiota in infants in the Copenhagen Prospective Study on Asthma in Childhood, a clinical study of a birth cohort of 411 high-risk children followed for 6 years by clinical assessments at 6-month intervals, as well as at acute symptom exacerbations. Bacterial flora was analyzed at 1 and 12 months of age by using molecular techniques based on 16S rRNA PCR combined with denaturing gradient gel electrophoresis, as well as conventional culturing. The main outcome measures were the development of allergic sensitization (skin test and specific serum IgE), allergic rhinitis, peripheral blood eosinophil counts, asthma, and atopic dermatitis during the first 6 years of life.

Results

We found that bacterial diversity in the early intestinal flora 1 and 12 months after birth was inversely associated with the risk of allergic sensitization (serum specific IgE P = .003; skin prick test P = .017), peripheral blood eosinophils (P = .034), and allergic rhinitis (P = .007). There was no association with the development of asthma or atopic dermatitis.

Conclusions

Reduced bacterial diversity of the infant’s intestinal flora was associated with increased risk of allergic sensitization, allergic rhinitis, and peripheral blood eosinophilia, but not asthma or atopic dermatitis, in the first 6 years of life. These results support the general hypothesis that an imbalance in the intestinal microbiome is influencing the development of lifestyle-related disorders, such as allergic disease.

Le texte complet de cet article est disponible en PDF.

Key words : Allergic sensitization, allergic rhinitis, peripheral blood eosinophils, atopic dermatitis, asthma, denaturing gradient gel electrophoresis, infants, gastrointestinal, microbiota, fecal microflora, human microbiome

Abbreviations used : COPSAC, DGGE, GEE, PCA


Plan


 N. L. was supported by a scholarship kindly given by the Chinese State. Copenhagen Prospective Study on Asthma in Childhood (COPSAC) is funded by private and public research funds, all listed on www.copsac.com. The Lundbeck Foundation, the Pharmacy Foundation of 1991, the Augustinus Foundation, the Danish Medical Research Council, and the Danish Pediatric Asthma Centre provide core support for COPSAC.
 Disclosure of potential conflict of interest: H. Bisgaard has been a lecturer for AstraZeneca and Merck; has consultant arrangements with Merck and Chiesi; and has provided legal consultation/expert witness testimony for the European Medicines Agency in cases related to the guidelines on pediatric studies for documenting asthma drugs. The rest of the authors have declared that they have no conflict of interest.


© 2011  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 128 - N° 3

P. 646 - septembre 2011 Retour au numéro
Article précédent Article précédent
  • IκB kinase–driven nuclear factor-κB activation in patients with asthma and chronic obstructive pulmonary disease
  • Rosalia Gagliardo, Pascal Chanez, Mirella Profita, Anna Bonanno, Giusy Daniela Albano, Angela Marina Montalbano, Flora Pompeo, Cesare Gagliardo, Anna Maria Merendino, Mark Gjomarkaj
| Article suivant Article suivant
  • Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease
  • Guillaume Geri, Benjamin Terrier, Michelle Rosenzwajg, Bertrand Wechsler, Maxime Touzot, Danielle Seilhean, Tu-Anh Tran, Bahram Bodaghi, Lucile Musset, Vassili Soumelis, David Klatzmann, Patrice Cacoub, David Saadoun

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.